The clinically meaningful efficacy of the anti-BAFF mAb, belimumab, in SLE clinical trials [48], [49] provides prima facie evidence that BAFF antagonism can be beneficial in at least some autoimmune disorders. The gene discussed is TNFSF13B; the disease is Autoimmunity.